and in studies of unsupervised, self-administered treatment
among patients who were not pregnant.23-25
Preliminary data suggest that closed-loop systems
may maintain near-normal glucose levels and
minimize the risk of nocturnal hypoglycemia
among pregnant women with type 1 diabetes.26,27
We performed a 4-week, randomized, crossover
study of an overnight closed-loop system, followed
by a 14-week continuation phase of dayand-night
closed-loop therapy, which encompassed
pregnancy-related challenges, including
antenatal hospital admission, labor, and delivery,
as well as postnatal adaptation.